Unlocking Visual Possibilities: Akari Therapeutics to Present at ARVO 2023!

Akari Therapeutics, Plc (Nasdaq: AKTX) is excited to attend ARVO 2023, the annual meeting of The Association for Research in Vision and Ophthalmology. The late-stage biotechnology company is developing advanced therapies for autoimmune and inflammatory diseases and will use the opportunity to meet with researchers, thought leaders, and potential partners.

Akari’s lead asset, investigational nomacopan, is a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4). The company is also developing a long-acting PAS-nomacopan as a potential treatment for geographic atrophy. Don’t miss out on this exciting opportunity to learn more about Akari Therapeutics’ innovative therapies!

This April, come experience the vibrant culture and unique atmosphere of New Orleans for the annual Association for Research in Vision and Ophthalmology (ARVO) 2023 conference!

Join over 10,000 vision researchers, clinicians, and scientists from around the world for a week of scientific sessions, poster presentations, and invited speaker sessions. ARVO 2023 is the perfect opportunity to gain knowledge, exchange ideas, and make connections – all while savoring the flavors and sights of the Crescent City.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a pioneering biotechnology company on a mission to develop advanced therapies for autoimmune and inflammatory diseases.

At the forefront of the company’s pipeline is investigational nomacopan, a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity.

The drug has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

Akari has also initiated a Phase 3 clinical trial program to investigate nomacopan for this indication. Moreover, the company is developing nomacopan for adult HSCT-TMA, as well as conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA).

Leave a Comment